share_log

Vertex Pharmaceuticals | 8-K: Current report

Vertex Pharmaceuticals | 8-K: Current report

福泰制药 | 8-K:重大事件
美股SEC公告 ·  05/15 16:55
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Incorporated held its annual meeting of shareholders on May 15, 2024. During the meeting, shareholders voted on several key proposals. The election of the Board of Directors was a primary focus, with Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry, and Suketu Upadhyay all being elected to serve until the 2025 annual meeting. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The 2023 compensation program for the company's named executive officers was approved on an advisory basis. A shareholder proposal regarding a special shareholder meeting improvement was also approved. However, a proposal concerning a report on racial and gender pay gaps was not approved. The results of the votes were documented and the report was signed by Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals.
Vertex Pharmaceuticals Incorporated held its annual meeting of shareholders on May 15, 2024. During the meeting, shareholders voted on several key proposals. The election of the Board of Directors was a primary focus, with Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry, and Suketu Upadhyay all being elected to serve until the 2025 annual meeting. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The 2023 compensation program for the company's named executive officers was approved on an advisory basis. A shareholder proposal regarding a special shareholder meeting improvement was also approved. However, a proposal concerning a report on racial and gender pay gaps was not approved. The results of the votes were documented and the report was signed by Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals.
Vertex 制药公司于 2024 年 5 月 15 日举行了年度股东大会。会议期间,股东们对几项关键提案进行了投票。董事会选举是主要焦点,桑吉塔·巴蒂亚、劳埃德·卡尼、艾伦·加伯、雷什玛·凯瓦尔拉马尼、米歇尔·拉加德、杰弗里·莱顿、戴安娜·麦肯齐、布鲁斯·萨克斯、珍妮弗·施耐德、南希·索恩伯里和苏克图·乌帕迪亚都当选任期至2025年年会。此外,股东批准任命安永会计师事务所为截至2024年12月31日的财政年度的独立注册会计师事务所。2023年公司指定执行官的薪酬计划是在咨询基础上获得批准的。一项关于改进股东特别会议的股东提案也获得批准。但是,一项关于种族和性别工资差距报告的提案未获批准。投票结果已记录在案,报告由Vertex Pharmicals执行副总裁兼首席法务官乔纳森·比勒签署。
Vertex 制药公司于 2024 年 5 月 15 日举行了年度股东大会。会议期间,股东们对几项关键提案进行了投票。董事会选举是主要焦点,桑吉塔·巴蒂亚、劳埃德·卡尼、艾伦·加伯、雷什玛·凯瓦尔拉马尼、米歇尔·拉加德、杰弗里·莱顿、戴安娜·麦肯齐、布鲁斯·萨克斯、珍妮弗·施耐德、南希·索恩伯里和苏克图·乌帕迪亚都当选任期至2025年年会。此外,股东批准任命安永会计师事务所为截至2024年12月31日的财政年度的独立注册会计师事务所。2023年公司指定执行官的薪酬计划是在咨询基础上获得批准的。一项关于改进股东特别会议的股东提案也获得批准。但是,一项关于种族和性别工资差距报告的提案未获批准。投票结果已记录在案,报告由Vertex Pharmicals执行副总裁兼首席法务官乔纳森·比勒签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息